menu toggle

New Year, New Hurdles: What’s in Store for Biosimilars in 2023

The Center for Biosimilars, Brian Biehn

On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.


For the full interview, please visit The Center for Biosimilars.